Search company, investor...

Predict your next investment

Ampersand Capital Partners company logo
Private Equity
ampersandcapital.com

Investments

141

Portfolio Exits

58

Funds

19

Partners & Customers

1

Service Providers

2

About Ampersand Capital Partners

Ampersand Capital Partners is a middle-market private equity firm focused on investments in the healthcare and industrial sectors. The company was founded in 1988 and is based in Wellesley, Massachusetts.

Headquarters Location

55 William St Suite 240

Wellesley, Massachusetts, 02481,

United States

781-239-0700

Want to inform investors similar to Ampersand Capital Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Ampersand Capital Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Ampersand Capital Partners in 2 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

S

Synthetic Biology

382 items

Latest Ampersand Capital Partners News

Sterling Medical Devices and RBC Medical Innovations Rebrand as Vantage MedTech

Sep 12, 2023

News provided by Share this article New Brand Reflects Vast Experience and Commitment to Continued Innovation in the Medical Technology Industry MOONACHIE, N.J. and LENEXA, Kan., Sept. 12, 2023 /PRNewswire/ -- Sterling Medical Devices and RBC Medical Innovations announced today the rebranding of the combined company as Vantage MedTech. Leveraging decades of industry experience and the specialized expertise of more than 150 medical device engineers, Vantage MedTech is poised to continue providing complete life cycle solutions to medical technology innovators, from concept through to product realization. The Company's integrated capabilities include full-systems development utilizing its software, industrial, mechanical and electrical engineering expertise, clinical and commercial scale manufacturing, and regulatory strategy consulting, all supported by the Company's robust quality systems. "We are thrilled to announce our new brand at this exciting juncture in our company's evolution", said David Montecalvo, CEO. "Vantage offers the MedTech industry a wide range of integrated engineering and technical expertise, resulting in faster time-to-market results for our clients. We are committed to partnering with our clients to accelerate commercialization of their life-changing medical devices and are dedicated to providing these solutions with the highest integrity, quality standards and excellence." About Vantage MedTech Vantage MedTech provides comprehensive design and manufacturing services, supporting the advancement of medical technologies from concept through to product realization. Partnering with the world's most innovative MedTech start-ups and large OEMs, we offer feasibility support, product development and prototyping, clinical and commercial manufacturing, and after-market services to support every phase of the product life cycle. Our clients can leverage our proprietary Advantage Platforms ™, accelerating product development timelines. Our manufacturing approach is structured to serve the changing needs of our clients, supporting small-quantity clinical or First-in-Human builds and can scale to accommodate full launch quantities. Vantage MedTech has offices in Moonachie, New Jersey and Lenexa, Kansas. Additional information is available at available at VantageMedTech.com , SterlingMedicalDevices.com , and RBCCorp.com . About Ampersand Capital Partners Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn . SOURCE Vantage MedTech

Ampersand Capital Partners Investments

141 Investments

Ampersand Capital Partners has made 141 investments. Their latest investment was in Vernal Biosciences as part of their Series B on June 6, 2023.

CBI Logo

Ampersand Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/27/2023

Series B

Vernal Biosciences

$20M

No

2

6/12/2023

Series B

NanoImaging Services

Yes

4

5/2/2023

Recap

P95

Yes

1

6/23/2022

Private Equity

Subscribe to see more

Subscribe to see more

10

6/7/2022

Series C - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/27/2023

6/12/2023

5/2/2023

6/23/2022

6/7/2022

Round

Series B

Series B

Recap

Private Equity

Series C - II

Company

Vernal Biosciences

NanoImaging Services

P95

Subscribe to see more

Subscribe to see more

Amount

$20M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

1

10

10

Ampersand Capital Partners Portfolio Exits

58 Portfolio Exits

Ampersand Capital Partners has 58 portfolio exits. Their latest portfolio exit was GenDx on August 17, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/17/2022

Acquired

$99M

11

2/18/2022

Acquired

$99M

2

2/18/2022

Acquired

$99M

3

1/12/2022

Merger

Subscribe to see more

$99M

Subscribe to see more

10

1/5/2022

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/17/2022

2/18/2022

2/18/2022

1/12/2022

1/5/2022

Exit

Acquired

Acquired

Acquired

Merger

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

11

2

3

10

10

Ampersand Capital Partners Acquisitions

27 Acquisitions

Ampersand Capital Partners acquired 27 companies. Their latest acquisition was iuvo BioScience on September 28, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/28/2022

$99M

Acq - Fin

1

8/30/2022

$99M

Acq - Fin

2

8/25/2022

$99M

Acq - Fin

1

7/1/2021

Subscribe to see more

$99M

Subscribe to see more

10

9/21/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2022

8/30/2022

8/25/2022

7/1/2021

9/21/2020

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acq - Fin

Acq - Fin

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Ampersand Capital Partners Fund History

19 Fund Histories

Ampersand Capital Partners has 19 funds, including Ampersand 2022.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/2/2022

Ampersand 2022

$1,200M

1

11/19/2020

Ampersand Continuation Fund

$670M

2

3/31/2020

Ampersand 2020

Multi-Stage Venture Capital

Open

$690M

3

3/19/2018

Ampersand Capital Partners Fund I

Subscribe to see more

Subscribe to see more

$99M

10

5/29/2015

Ampersand 2014 LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

9/2/2022

11/19/2020

3/31/2020

3/19/2018

5/29/2015

Fund

Ampersand 2022

Ampersand Continuation Fund

Ampersand 2020

Ampersand Capital Partners Fund I

Ampersand 2014 LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Amount

$1,200M

$670M

$690M

$99M

$99M

Sources

1

2

3

10

10

Ampersand Capital Partners Partners & Customers

1 Partners and customers

Ampersand Capital Partners has 1 strategic partners and customers. Ampersand Capital Partners recently partnered with GenDx on May 5, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

5/6/2019

Partner

Netherlands

Ampersand Capital backs GenDx

The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market .

5

Date

5/6/2019

Type

Partner

Business Partner

Country

Netherlands

News Snippet

Ampersand Capital backs GenDx

The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market .

Sources

5

Ampersand Capital Partners Service Providers

2 Service Providers

Ampersand Capital Partners has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Service Type

Partnership data by VentureSource

Ampersand Capital Partners Team

8 Team Members

Ampersand Capital Partners has 8 team members, including , .

Name

Work History

Title

Status

Richard A. Charpie

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Richard A. Charpie

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.